What’s new

• Board approved acquisition of 51% in Dubai's Blue Tree Clinics for ₹19.84 crore.
• Target clocked FY25 revenue of ~₹23.7 crore, or 29% of GKSL's consolidated revenue.
• Deal expands GKSL beyond kidney into plastic surgery, cosmetics, dental, chiropractic.

Why it matters

This is GKSL's first overseas move and a material shift from its kidney focus. For a micro-cap, the target's revenue is sizable, and the binding nature reduces execution risk. The diversification could unlock a new growth vector, but integration in a new geography carries its own challenges.

What we’re watching

• Shareholder approval for IPO object variation via postal ballot.
• How GKSL integrates Blue Tree's operations in the UAE.
• Potential earnings contribution from Blue Tree, likely in H2 FY26.

The full read

Gujarat Kidney And Super Speciality Ltd is buying 51% of Dubai-based polyclinic Blue Tree Clinics for ₹19.84 crore in cash. This is the company's first overseas acquisition and a sharp pivot from its kidney-focussed operations in India. Blue Tree posted FY25 revenue of AED 10.54 million (roughly ₹23.7 crore) and net profit of AED 3.14 million, a business that alone accounts for 29% of GKSL's consolidated revenue. The deal is structured as a binding share purchase agreement, closing within 50 days in two tranches, lowering execution risk. For a micro-cap with a market cap of ₹1,013 crore and trailing revenue growth of 212.6%, this acquisition opens a new chapter in plastic surgery, cosmetics, dental, and chiropractic services. Integration and cross-border management are the open questions, but the strategic logic of diversifying away from single-speciality dependence into a growing UAE healthcare market is clear. The board also moved to vary IPO objects, signalling a shift in capital deployment priorities. This is a materially significant event that could reshape GKSL's growth trajectory.

Primary source: BSE · NSE